Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2023-10-24
DOI
10.1080/14740338.2023.2274946
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Use of Electronic Health Record Data for Drug Safety Signal Identification: A Scoping Review
- (2023) Sharon E. Davis et al. DRUG SAFETY
- Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study
- (2023) Kohei Kaku et al. Expert Opinion On Drug Safety
- Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
- (2023) Brian Olshansky et al. Journal of the American Heart Association
- Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment
- (2023) Yamin Shu et al. DRUG SAFETY
- Prevalence of statin intolerance: a meta-analysis
- (2022) Ibadete Bytyçi et al. EUROPEAN HEART JOURNAL
- Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications
- (2022) Massimiliano Ruscica et al. CARDIOVASCULAR RESEARCH
- Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
- (2022) Haoning Guo et al. Frontiers in Pharmacology
- Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
- (2022) Michele Fusaroli et al. DRUG SAFETY
- Omega-3 and cardiovascular prevention – Is this still a choice?
- (2022) Massimiliano Ruscica et al. PHARMACOLOGICAL RESEARCH
- Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation
- (2022) Nazrul Islam et al. American Journal of Cardiovascular Drugs
- Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid
- (2022) M. John Chapman et al. PHARMACOLOGY & THERAPEUTICS
- Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
- (2022) Yamin Shu et al. Frontiers in Public Health
- Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
- (2021) Juliana Setyawan et al. DRUG SAFETY
- The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database
- (2021) Faizan Mazhar et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system
- (2021) Yamin Shu et al. Expert Opinion On Drug Safety
- Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
- (2020) Milo Gatti et al. European Journal of Preventive Cardiology
- Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial
- (2020) Are Annesønn Kalstad et al. CIRCULATION
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
- (2020) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
- (2019) Emelia J. Benjamin et al. CIRCULATION
- Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial
- (2019) Omar Sheikh et al. Cardiovascular Diabetology
- Time‐to‐onset analysis of amiodarone‐associated thyroid dysfunction
- (2019) Sayoko Kinoshita et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Risk of Cardiovascular Events in Patients with Hypertriglyceridemia: A Review of Real‐World Evidence
- (2019) Peter P. Toth et al. DIABETES OBESITY & METABOLISM
- Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
- (2018) Om P. Ganda et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey
- (2018) Wenjun Fan et al. Journal of Clinical Lipidology
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
- (2017) Gregory A. Roth et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: A critical reassessment
- (2013) George E. Billman PHARMACOLOGY & THERAPEUTICS
- A Review of Statistical Methods for Safety Surveillance
- (2013) Lan Huang et al. Therapeutic Innovation & Regulatory Science
- Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
- (2012) Christie M. Ballantyne et al. AMERICAN JOURNAL OF CARDIOLOGY
- A Signal Detection Method to Detect Adverse Drug Reactions Using a Parametric Time-to-Event Model in Simulated Cohort Data
- (2012) Victoria R. Cornelius et al. DRUG SAFETY
- Ethnic differences in the ability of triglyceride levels to identify insulin resistance
- (2007) Anne E. Sumner et al. ATHEROSCLEROSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started